Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)
- De Laurentiis, M.
- Borstnar, S.
- Campone, M.
- Warner, E.
- Bofill, J.S.
- Jacot, W.
- Dent, S.
- Martin, M.
- Ring, A.
- Cottu, P.
- Lu, J.
- Ciruelos, E.
- Azim, H.A.
- Chatterjee, S.
- Zhou, K.
- Wu, J.
- Menon-Singh, L.
- Zamagni, C.
ISSN: 1573-7217, 0167-6806
Année de publication: 2022
Volumen: 191
Número: 1
Pages: 223-224
Type: Erreur